APAC Artificial Intelligence (AI) in Drug Discovery Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143112
- Pages: 225
-
Format:
Short Description
Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market, By Application (Novel Drug Candidates, Drug Optimization and Repurposing Preclinical Testing and Approval, Drug Monitoring, Finding New Diseases Associated Targets and Pathways, Understanding Disease Mechanisms, Aggregating and Synthesizing Information, Formation & Qualification of Hypotheses, De Novo Drug Design, Finding Drug Targets of an Old Drug, and Others), Technology (Machine Learning, Deep Learning, Natural Language Processing, and Others), Drug Type (Small Molecule and Large Molecule), Offering (Software and Services.), Indication (Immuno-Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, and Others), End Use (Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, and Others), Country (China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, New Zealand, Philippines, Indonesia, and Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition
Artificial Intelligence (AI) has caught the attention and minds of medical technology practitioners in the past few years, as several companies and major research laboratories have worked to perfect these technologies for clinical use. The first commercialized demonstrations of how AI (also known as Deep Learning (DL), Machine Learning (ML), or Artificial Neural Networks (ANNs)) could assist clinicians are now available. These systems could lead to a paradigm shift in clinician workflow, increase productivity while simultaneously enhancing treatment and patient throughput. AI for drug discovery is a technology that uses machines to simulate human intelligence in order to solve complicated challenges in the drug development procedure. The adoption of AI solutions in the clinical trial process eliminates possible obstacles, reduces clinical trial cycle time, and increases the productivity and accuracy of the clinical trial process. Therefore, the adoption of these advanced AI solutions in drug discovery processes is gaining popularity amongst life science industry stakeholders. In the pharmaceutical sector, it aids in the discovery of novel compounds, therapeutic target identification, and the development of customized medications. AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases.
Market Segmentation
Asia Pacific Artificial Intelligence (AI) in drug discovery market is categorized into six notable segments: application, technology, drug type, offering, indication, and end use.
On the basis of application, the market is segmented into novel drug candidates, drug optimization and repurposing preclinical testing and approval, drug monitoring, finding new diseases associated targets and pathways, understanding disease mechanisms, aggregating and synthesizing information, formation & qualification of hypotheses, de novo drug design, finding drug targets of an old drug, and others
On the basis of technology, the market is segmented into Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and others
On the basis of drug type, the market is segmented into small molecule and large molecule
On the basis of offering, the market is segmented into software and services
On the basis of indication, the market is segmented into immuno-oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and others
On the basis of end use, the market is segmented into pharmaceutical & biotechnology companies, Contract Research Organizations (CROs), research centers and academic institutes, and others
Market Players
The key market players operating in the Asia-Pacific Artificial Intelligence (AI) in drug discovery market are listed below:
Envisagenics
Owkin Inc.
BERG LLC
Schrdinger, Inc.
XtalPi Inc.
BIOAGE Inc.
TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET 33
1.4 CURRENCY AND PRICING 35
1.5 LIMITATIONS 35
1.6 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
2.1 MARKETS COVERED 39
2.2 GEOGRAPHICAL SCOPE 40
2.3 YEARS CONSIDERED FOR THE STUDY 41
2.4 DBMR TRIPOD DATA VALIDATION MODEL 42
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.6 MULTIVARIATE MODELLING 46
2.7 MARKET APPLICATION COVERAGE GRID 47
2.8 SOURCE LIFELINE CURVE 48
2.9 DBMR MARKET POSITION GRID 49
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHT 56
4.1 PESTEL ANALYSIS 57
4.2 PORETSRS FIVE FORCES 58
5 MARKET OVERVIEW 59
5.1 DRIVERS 61
5.1.1 THE RISE IN INCIDENCE OF CHRONIC DISEASES PROPELS NEED FOR ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY 61
5.1.2 STRATEGIC COLLABORATIONS, PARTNERSHIPS, AND PRODUCTS LAUNCH 61
5.1.3 REDUCTION IN TOTAL TIME INVOLVED IN DRUG DISCOVERY PROCESS 62
5.1.4 ADVANCEMENT OF ARTIFICIAL INTELLIGENCE IN THE HEALTHCARE INDUSTRY 62
5.2 RESTRAINTS 63
5.2.1 HIGH COST ASSOCIATED WITH TECHNOLOGY AND TECHNICAL LIMITATIONS 63
5.2.2 DISADVANTAGES AND RISKS ASSOCIATED WITH AI IN DRUG DISCOVERY 63
5.2.3 LACK OF AVAILABLE QUALITY DATA 63
5.3 OPPORTUNITIES 64
5.3.1 RISE IN THE INVESTMENTS FOR R&D 64
5.3.2 RISING HEALTHCARE INFRASTRUCTURE 64
5.3.3 DEVELOPMENT OF NOVEL TOOLS 65
5.4 CHALLENGES 65
5.4.1 THE ASIA PACIFIC SHORTAGE OF AI TALENT 65
5.4.2 ETHICAL, LEGAL, AND REGULATORY ISSUES FOR AI ADOPTION IN THE PHARMACEUTICAL SCIENCES 66
6 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING 67
6.1 OVERVIEW 68
6.2 SOFTWARE 71
6.2.1 INTEGRATED 72
6.2.2 STANDALONE 72
6.3 SERVICES 72
7 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 74
7.1 OVERVIEW 75
7.2 MACHINE LEARNING (ML) 78
7.2.1 SUPERVISED LEARNING 79
7.2.2 UNSUPERVISED LEARNING 79
7.2.3 REINFORCEMENT LEARNING 79
7.3 DEEP LEARNING 79
7.4 NATURAL LANGUAGE PROCESSING (NLP) 80
7.5 OTHERS 81
8 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY DRUG TYPE 82
8.1 OVERVIEW 83
8.2 SMALL MOLECULE 86
8.3 LARGE MOLECULE 86
9 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION 88
9.1 OVERVIEW 89
9.2 NOVEL DRUG CANDIDATES 92
9.2.1 PREDICT BIOACTIVITY OF SMALL MOLECULE 93
9.2.2 IDENTIFY BIOLOGICS TARGET 93
9.2.3 OTHERS 93
9.3 DRUG OPTIMISATION AND RE-PURPOSING PRE-CLINICAL TESTING AND APPROVAL 93
9.4 DRUG MONITORING 94
9.5 AGGREGATING AND SYNTHESIZING INFORMATION 95
9.6 DE NOVO DRUG DESIGN 95
9.7 FINDING DRUG TARGETS OF AN OLD DRUG 96
9.8 FORMATION & QUALIFICATION OF HYPOTHESES 97
9.9 UNDERSTANDING DISEASE MECHANISMS 98
9.10 FINDING NEW DISEASE-ASSOCIATED TARGETS AND PATHWAYS 98
9.11 OTHERS 99
10 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION 101
10.1 OVERVIEW 102
10.2 IMMUNE-ONCOLOGY 105
10.2.1 BREAST CANCER 106
10.2.2 LUNG CANCER 106
10.2.3 COLORECTAL CANCER 106
10.2.4 PROSTATE CANCER 106
10.2.5 PANCREATIC CANCER 106
10.2.6 BRAIN CANCER 106
10.2.7 LEUKEMIA 107
10.2.8 OTHERS 107
10.3 NEURODEGENERATIVE DISEASES 107
10.4 CARDIOVASCULAR DISEASES 108
10.5 METABOLIC DISEASES 108
10.6 OTHERS 109
11 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY END USE 110
11.1 OVERVIEW 111
11.2 CONTRACT RESEARCH ORGANIZATIONS 114
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 114
11.4 RESEARCH CENTERS AND ACADEMIC INSTITUTES 115
11.5 OTHERS 116
12 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION 117
12.1 ASIA-PACIFIC 118
12.1.1 CHINA 126
12.1.2 JAPAN 130
12.1.3 SOUTH KOREA 134
12.1.4 INDIA 138
12.1.5 AUSTRALIA & NEW ZEALAND 142
12.1.6 SINGAPORE 146
12.1.7 THAILAND 150
12.1.8 MALAYSIA 154
12.1.9 INDONESIA 158
12.1.10 PHILIPPINES 162
12.1.11 REST OF ASIA-PACIFIC 166
13 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 167
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 167
14 SWOT ANALYSIS 168
15 COMPANY PROFILES 169
15.1 NVIDIA CORPORATION 169
15.1.1 COMPANY SNAPSHOT 169
15.1.2 REVENUE ANALYSIS 169
15.1.3 COMPANY SHARE ANALYSIS 170
15.1.4 PRODUCT PORTFOLIO 170
15.1.5 RECENT DEVELOPMENTS 170
15.2 MICROSOFT 171
15.2.1 COMPANY SNAPSHOT 171
15.2.2 REVENUE ANALYSIS 171
15.2.3 COMPANY SHARE ANALYSIS 172
15.2.4 PRODUCT PORTFOLIO 172
15.2.5 RECENT DEVELOPMENT 172
15.3 IBM CORP 173
15.3.1 COMPANY SNAPSHOT 173
15.3.2 REVENUE ANALYSIS 173
15.3.3 COMPANY SHARE ANALYSIS 174
15.3.4 PRODUCT PORTFOLIO 174
15.3.5 RECENT DEVELOPMENT 174
15.4 SCHRDINGER, INC. 175
15.4.1 COMPANY SNAPSHOT 175
15.4.2 REVENUE ANALYSIS 175
15.4.3 COMPANY SHARE ANALYSIS 176
15.4.4 PRODUCT PORTFOLIO 176
15.4.5 RECENT DEVELOPMENTS 176
15.5 BERG LLC 178
15.5.1 COMPANY SNAPSHOT 178
15.5.2 COMPANY SHARE ANALYSIS 178
15.5.3 PRODUCT PORTFOLIO 178
15.5.4 RECENT DEVELOPMENTS 179
15.6 ARDIGEN 180
15.6.1 COMPANY SNAPSHOT 180
15.6.2 PRODUCT PORTFOLIO 180
15.6.3 RECENT DEVELOPMENTS 180
15.7 EXSCIENTIA 181
15.7.1 COMPANY SNAPSHOT 181
15.7.2 REVENUE ANALYSIS 181
15.7.3 PRODUCT PORTFOLIO 182
15.7.4 RECENT DEVELOPMENTS 182
15.8 ARIA PHARMACEUTICALS, INC. 183
15.8.1 COMPANY SNAPSHOT 183
15.8.2 PRODUCT PORTFOLIO 183
15.8.3 RECENT DEVELOPMENTS 183
15.9 ATOMWISE INC. 185
15.9.1 COMPANY SNAPSHOT 185
15.9.2 PRODUCT PORTFOLIO 185
15.9.3 RECENT DEVELOPMENTS 185
15.10 BENEVOLENT AI 187
15.10.1 COMPANY SNAPSHOT 187
15.10.2 REVENUE ANALYSIS 187
15.10.3 PRODUCT PORTFOLIO 188
15.10.4 RECENT DEVELOPMENTS 188
15.11 BIOAGE INC., 189
15.11.1 COMPANY SNAPSHOT 189
15.11.2 PRODUCT PORTFOLIO 189
15.11.3 RECENT DEVELOPMENTS 189
15.12 CLOUD 190
15.12.1 COMPANY SNAPSHOT 190
15.12.2 PRODUCT PORTFOLIO 190
15.12.3 RECENT DEVELOPMENT 190
15.13 CYCLICA 191
15.13.1 COMPANY SNAPSHOT 191
15.13.2 PRODUCT PORTFOLIO 191
15.13.3 RECENT DEVELOPMENTS 191
15.14 DEEP GENOMICS 193
15.14.1 COMPANY SNAPSHOT 193
15.14.2 PRODUCT PORTFOLIO 193
15.14.3 RECENT DEVELOPMENTS 193
15.15 ENVISAGENICS 195
15.15.1 COMPANY SNAPSHOT 195
15.15.2 PRODUCT PORTFOLIO 195
15.15.3 RECENT DEVELOPMENTS 195
15.16 INSILICO MEDICINE 197
15.16.1 COMPANY SNAPSHOT 197
15.16.2 PRODUCT PORTFOLIO 197
15.16.3 RECENT DEVELOPMENTS 197
15.17 NUMEDII, INC. 199
15.17.1 COMPANY SNAPSHOT 199
15.17.2 PRODUCT PORTFOLIO 199
15.17.3 RECENT DEVELOPMENT 199
15.18 OWKIN INC. 200
15.18.1 COMPANY SNAPSHOT 200
15.18.2 PRODUCT PORTFOLIO 200
15.18.3 RECENT DEVELOPMENT 200
15.19 XTALPI INC. 201
15.19.1 COMPANY SNAPSHOT 201
15.19.2 PRODUCT PORTFOLIO 201
15.19.3 RECENT DEVELOPMENTS 201
16 QUESTIONNAIRE 203
17 RELATED REPORTS 206
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
